Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

222990

registered interest
date	23/02/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether the specialised services circular issued by NHS England on 30 September 2013, ID SSC1315, on Individual Funding Requests for Clinically Urgent Treatment Outside Established Policy, remains in force; whether individual requests for treatments for which a cohort policy is in development will not be funded without evidence of clinical exceptionality; how many individual funding requests for (a) all treatment and (b) Duodopa were (i) approved and (ii) not approved under the (A) critical clinically urgent criteria and (B) urgent non-clinical criteria in each month in which that circular has been in force; if all requests made under the urgent non-clinical criteria received expert opinion from the Chair of the relevant clinical reference group within two weeks; and if he will make a statement.
tabling member constituency	Sutton and Cheam
tabling member printed	Paul Burstow
uin	224981
answer	answer is ministerial correction date of answer 02/03/2015 answer text <p>NHS England has confirmed that, to be successful, any individual funding request (IFR) for Duodopa must demonstrate exceptionality against the cohort of patients with Parkinson's disease in NHS England’s draft commissioning policy.</p><p> </p><p> </p><p> </p><p>Although it does not routinely commission Duodopa for the treatment of advanced Parkinson’s disease, NHS England has advised that, it will consider funding this treatment in exceptional clinical circumstances. Clinicians can submit IFRs for this treatment to NHS England on behalf of their patients.</p><p> </p><p> </p><p> </p><p>NHS England has IFRs for all treatments/interventions were received by NHS England through the standard IFR process. 238 of these were considered by an NHS England IFR panel.</p><p> </p><p> </p><p> </p><p>21 requests for Duodopa were received as shown in the table.</p><p> </p><p> </p><p> </p><table><tbody><tr><td><p>IFR team</p></td><td><p>Indication</p></td><td><p>Number of IFRs received</p></td><td><p>Approved</p></td><td><p>Not Approved</p></td></tr><tr><td><p>Midlands and East</p></td><td><p>Duodopa</p></td><td><p>3</p></td><td><p>0</p></td><td><p>3</p></td></tr><tr><td><p>North</p></td><td><p>Duodopa</p></td><td><p>5</p></td><td><p>0</p></td><td><p>5</p></td></tr><tr><td><p>London</p></td><td><p>Duodopa</p></td><td><p>11</p></td><td><p>0</p></td><td><p>11</p></td></tr><tr><td><p>South</p></td><td><p>Duodopa</p></td><td><p>2</p></td><td><p>0</p></td><td><p>2</p></td></tr></tbody></table><p> </p><p><em>Source:</em> NHS England</p><p> </p><p><strong> </strong></p><p> </p><p>NHS England is unable to provide monthly figures due to the small volume of requests as this could lead to the identification of individual patients.</p><p> </p><p> </p><p> </p><p>NHS England has advised that the SSC1315 on Individual Funding Requests for Clinically Urgent Treatment Outside Established Policy has officially expired but has been maintained whilst a review is taking place regarding how such cases will be handled in the future.</p><p> </p><p> </p><p> </p><p>It has confirmed that not all non-clinical IFRs require an expert opinion. This is only sought when it is felt that further expert opinion is required. It should be noted that Duodopa became NHS England’s responsibility from April 2014. Prior to then cases were considered by clinical commissioning groups.</p><p> </p><p> </p><p> </p><p>Details of IFRs processed under specialised services circular SSC1315 for the period 1 October 2013 to 24 February 2015 are shown in the table:</p><p> </p><p><strong> </strong></p><p> </p><table><tbody><tr><td rowspan="2"><p>IFR team</p></td><td rowspan="2"><p>Indication</p></td><td rowspan="2"><p>Number of IFRs received</p></td><td colspan="2"><p>Approved</p></td><td colspan="2"><p>Not Approved</p></td></tr><tr><td><p>critical clinically urgent</p></td><td><p>urgent non-clinical</p></td><td><p>critical clinically urgent</p></td><td><p>urgent non-clinical</p></td></tr><tr><td rowspan="2"><p>Midlands &amp; East</p></td><td><p>All</p></td><td><p>11</p></td><td><p>5</p></td><td><p>6</p></td><td><p>0</p></td><td><p>0</p></td></tr><tr><td><p>Duodopa</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td></tr><tr><td rowspan="2"><p>North</p></td><td><p>All</p></td><td><p>13</p></td><td><p>12</p></td><td><p>0</p></td><td><p>1</p></td><td><p>0</p></td></tr><tr><td><p>Duodopa</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td></tr><tr><td rowspan="2"><p>London</p></td><td><p>All</p></td><td><p>37</p></td><td><p>31</p></td><td><p>3</p></td><td><p>3</p></td><td><p>0</p></td></tr><tr><td><p>Duodopa</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td></tr><tr><td rowspan="2"><p>South</p></td><td><p>All</p></td><td><p>18</p></td><td><p>10</p></td><td><p>1</p></td><td><p>3</p></td><td><p>4</p></td></tr><tr><td><p>Duodopa</p></td><td><p>6</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td></tr></tbody></table><p> </p><p><em>Source:</em> NHS England</p><p> </p><p> </p><p> </p><p>Further information about NHS England’s IFR process is available at:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/04/cp-03.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/04/cp-03.pdf</a></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 224942 224946 question first answered 02/03/2015 17:40:04 answering member 4020 label Biography information for George Freeman
tabling member	204 label Biography information for Paul Burstow

222997

registered interest
date	23/02/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Clinical Priorities Advisory Group
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether NHS England is continuing to consider whether to publish the minutes of meetings of the Clinical Priorities Advisory Group; what factors it is taking into consideration before making that decision; and if he will make a statement.
tabling member constituency	Sutton and Cheam
tabling member printed	Paul Burstow
uin	224943
answer	answer is ministerial correction date of answer 02/03/2015 answer text <p>NHS England has advised that it is planning to publish the Clinical Priorities Advisory Group (CPAG) minutes for the meeting which took place in February. It plans to publish these minutes and others following the current NHS England consultation on the principles underpinning prioritisation in specialised services. The consultation closes on 27 April 2015 and can be found at:</p><p> </p><p> </p><p> </p><p><a href="http://www.engage.england.nhs.uk/consultation/investing-in-specialised-commissioning" target="_blank">www.engage.england.nhs.uk/consultation/investing-in-specialised-commissioning</a></p><p> </p><p> </p><p> </p><p>NHS England has advised that it intends to routinely publish minutes of CPAG meetings in the future, and is considering how to make available minutes of previous meetings.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 02/03/2015 17:42:49 answering member 3918 label Biography information for Jane Ellison
tabling member	204 label Biography information for Paul Burstow

223001

registered interest
date	23/02/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Levodopa
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, on what basis NHS England's Clinical Priorities Advisory Group has recommended that Duodopa should not be routinely commissioned by NHS England; what factors NHS England's Clinical Priorities Advisory Group took into consideration in reaching that recommendation; what advice NHS England's Clinical Priorities Advisory Group sought from patient representatives in reaching that decision; what process NHS England follows to allow interested parties to appeal recommendations by the Clinical Priorities Advisory Group; and if he will make a statement.
tabling member constituency	Sutton and Cheam
tabling member printed	Paul Burstow
uin	224941
answer	answer is ministerial correction date of answer 02/03/2015 answer text <p>NHS England has advised that its Neuroscience Clinical Reference Group (CRG) carefully reviewed the clinical evidence for the treatment of advanced Parkinson’s disease with Duodopa (co-careldopa) and made a recommendation to the Clinical Priorities Advisory Group (CPAG).</p><p> </p><p> </p><p> </p><p>CPAG accepted the CRG’s recommendation that Duodopa should not be routinely commissioned for treatment of this condition and, in turn, made this recommendation to the Directly Commissioned Services Committee of the NHS England Board. The Board committee endorsed the recommendation in June 2014.</p><p> </p><p> </p><p> </p><p>Both patients and carers were involved in the decision-making process. There are four patient /carer representatives on the CRG, and patient and public stakeholders registered with the CRG were given an opportunity to feed in their views before the Group made its recommendations to CPAG. CPAG’s membership includes a lay chair and four patient representatives.</p><p> </p><p> </p><p> </p><p>Further work has been undertaken on Duodopa since NHS England’s Board endorsed CPAG’s decision in June 2014 and NHS England will reconsider whether or not to commission this treatment, alongside a number of other specialised treatments, later this year.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 02/03/2015 17:47:01 answering member 4020 label Biography information for George Freeman
tabling member	204 label Biography information for Paul Burstow

223004

registered interest
date	23/02/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will request that NHS England review its policy on individual funding requests.
tabling member constituency	Sutton and Cheam
tabling member printed	Paul Burstow
uin	224949
answer	answer is ministerial correction date of answer 02/03/2015 answer text <p>We have no such plans. We understand that NHS England is currently reviewing its generic policies, including its interim commissioning policy on individual funding requests.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 02/03/2015 17:45:14 answering member 4020 label Biography information for George Freeman
tabling member	204 label Biography information for Paul Burstow